Contingent Consideration (Earn-outs) in M&A
Why the 'purchase price' a company reports for an acquisition on the day the deal closes might not be the full amount it actually ends up paying — and why that gap can keep moving even years after the acquisition.
In plain English
Imagine a large pharma company acquires a smaller biotech firm for an upfront payment of ₹500 crore, PLUS an additional ₹300 crore that will only be paid if the acquired company's lead drug candidate successfully receives regulatory approval within the next 3 years — a common structure called an 'earn-out', designed to bridge a genuine valuation gap between what the buyer thinks the business is worth today and what the seller believes it could be worth if things go well. On the day the deal closes, how much should the buyer record as the total 'purchase price' for accounting purposes: just the ₹500 crore certain payment, or the full potential ₹800 crore? And what happens to the accounting if the drug approval outcome later becomes clearer, one way or the other?
Words you'll need first
A portion of an acquisition's total purchase price that depends on future events or performance targets being met — commonly tied to revenue targets, profit targets, or specific milestones like regulatory approval. Ind AS 103 requires the ACQUIRER to estimate the FAIR VALUE of this contingent payment obligation on day one — a genuine, probability-weighted estimate, not simply the maximum potential amount, and not zero just because the outcome is still uncertain.
After the acquisition closes, the contingent consideration liability must be REMEASURED to its current fair value at each subsequent reporting date, right up until the earn-out period ends, with any change flowing through the P&L. This is genuinely different from the Purchase Price Allocation and Goodwill calculation itself, which is generally fixed as of the acquisition date.
A worked example, with numbers
| Item | ₹ crore |
|---|---|
| Upfront payment | 500 |
| Contingent consideration — initial fair value (acquisition date) | 150 |
| Total "purchase price" used for Goodwill calculation | 650 |
| Contingent consideration — revised fair value (1 year later) | 250 |
| Additional expense recognised in Year 1 P&L (250 − 150) | 100 |
- The company's initial Goodwill calculation uses ₹650 crore as the effective purchase price — not the full ₹800 crore maximum potential payout, and not just the ₹500 crore certain portion.
- A year later, purely because the underlying drug's regulatory prospects have genuinely improved, the company has to recognise an ADDITIONAL ₹100 crore expense, even though it hasn't paid a single additional rupee yet.
- This creates a genuinely counterintuitive pattern: GOOD news about an acquired business's post-deal performance can create a P&L EXPENSE for the acquirer, because it means the acquirer is now more likely to owe more money under the earn-out terms.
- If the drug approval process had instead gone poorly, the company would instead recognise a GAIN — reducing its contingent consideration liability to reflect the now-lower expected payout.
What it does to the financial statements
Impact on the P&L
- Changes in the estimated fair value of contingent consideration flow through the P&L, creating genuine, sometimes counterintuitive, earnings volatility tied to the ACQUIRED business's post-deal performance, not the acquirer's own core operations.
- An acquirer with several outstanding earn-out obligations from past acquisitions can show meaningful P&L volatility, in either direction, purely from milestone-related remeasurements, disconnected from how well its OWN core business is performing.
- Unlike the initial Goodwill figure, fixed at the acquisition date, the contingent consideration liability remains genuinely 'live' and subject to ongoing remeasurement throughout the earn-out period.
- Analysts need to specifically identify and separate out contingent consideration remeasurement gains and losses from core operating performance, given how disconnected these figures can be from underlying business trends.
Impact on the Balance Sheet
- The contingent consideration obligation sits on the balance sheet as a liability, remeasured to fair value at each reporting date, distinct from the fixed Goodwill figure from the original Purchase Price Allocation.
- As the earn-out period progresses, this liability moves toward either its final settlement amount (if achieved) or zero (if definitively missed), with the corresponding P&L impact recognised along the way.
- A company with substantial outstanding contingent consideration obligations carries a real, quantifiable future cash obligation that doesn't show up as prominently as ordinary borrowings.
- For acquisitions with a SIGNIFICANT earn-out component, a reader trying to understand the buyer's TRUE total cost needs to track the contingent consideration's evolving fair value, not just the headline upfront payment figure.
Which standard covers this
In India this is governed by Ind AS 103 – Business Combinations, the same standard covered in the Goodwill & Impairment article, requiring contingent consideration to be recognised at fair value on the acquisition date and subsequently remeasured through the P&L.
How it's recognised globally
Globally, the equivalent is IFRS 3, and Ind AS 103 mirrors its contingent consideration recognition and subsequent-remeasurement-through-P&L approach closely. Under US GAAP, equivalent guidance sits in ASC 805, sharing broadly the same fundamental treatment — a genuinely significant, deliberate convergence point in global M&A accounting, since older practice historically allowed contingent consideration to be recognised only when it actually became payable, rather than estimated at fair value upfront.
Real example — Indian listed company
Piramal Enterprises, with its history of pharmaceutical and healthcare acquisitions both in India and internationally, is a representative real-world example of the kind of Indian company likely to structure at least some of its M&A activity using contingent consideration or earn-out arrangements, a common structuring tool in pharma and healthcare dealmaking specifically because so much of an acquired drug or healthcare business's ultimate value genuinely depends on uncertain future events — regulatory approvals, clinical trial outcomes, or commercial sales milestones. For companies in genuinely milestone-dependent sectors like pharma, earn-out structures are a rational, common way to bridge valuation disagreements between buyer and seller, and the accounting mechanics this article describes — an initial probability-weighted fair value estimate, followed by ongoing remeasurement through the P&L — are a routine, real feature of how such acquisitions get reported in the years following deal completion.
Where you'll see this
Related concepts
Goodwill & Impairment
Why a company can pay ₹1,000 crore to buy a business worth ₹600 crore on paper — and how accountants decide, every year after, whether that extra ₹400 crore was money well spent.
Consolidation & Non-Controlling Interest
Why a company's own standalone accounts can show a modest business, while its 'consolidated' accounts — the ones investors actually look at — show a much bigger empire, built entirely out of businesses it doesn't fully own.
Associates & Joint Ventures (Equity Method)
Why owning 20% of a company can sometimes mean showing 100% of nothing on your balance sheet — and other times showing a single number that quietly grows every year, even if you never buy another share.